Compare · ANIP vs LLY
ANIP vs LLY
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIP and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.04T, about 573.5x ANIP ($1.81B).
- LLY has been more active in the news (13 items in the past 4 weeks vs 7 for ANIP).
- LLY has more recent analyst coverage (25 ratings vs 11 for ANIP).
- Company
- ANI Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $1.81B
- $1.04T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 13
- Recent ratings
- 11
- 25
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ANIP
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)
- Director Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)
- Director Tannenbaum Renee P was granted 4,357 shares, increasing direct ownership by 17% to 29,514 units (SEC Form 4)
- Director Pera Antonio R was granted 4,357 shares, increasing direct ownership by 19% to 27,017 units (SEC Form 4)
- Director Leonard Matthew J was granted 4,357 shares, increasing direct ownership by 63% to 11,221 units (SEC Form 4)
- Director Haughey Thomas was granted 4,357 shares and sold $161,760 worth of shares (2,000 units at $80.88) as part of a pre-agreed trading plan, increasing direct ownership by 6% to 38,878 units (SEC Form 4)
- SVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $264,960 worth of shares (3,312 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
Latest LLY
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials